---
company: Seres Therapeutics, Inc.
ticker: MCRB
form: 8-K
filed: 2026-11-04
accepted: 2026-11-04T12:05:12+00:00
accession: 0001193125-26-446185
source: https://www.sec.gov/Archives/edgar/data/1609809/000119312526446185/
quarterly_report: https://www.sec.gov/Archives/edgar/data/1609809/000119312526446427/
---

# Seres Therapeutics (MCRB) Q3 2026 earnings

## Header

- Company: Seres Therapeutics, Inc.
- Reported: 2026-11-04 07:05 BMO ET
- Source: 8-K only — accession 0001193125-26-446185, Item 2.02 + Exhibit 99.1
- Verdict: Q3 2026 net loss narrowed to $16.3 million from $8.2 million in Q3 2025, driven by a $27.2 million gain on the VOWST sale and a $5.7 million asset impairment, while operating expenses declined 27% YoY.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---:|---:|---|
| EPS (GAAP) | -$1.63 | -273% | -255% | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $16.7M (-27% YoY)
- One-offs in the quarter: Gain on sale of VOWST Business $27.2M; Impairment of long-lived assets $5.7M
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Cash and cash equivalents | $17.5M | $15.6M | — | +12% |
| Weighted average common shares outstanding - diluted | 9,982,031 | 9,747,138 | 8,743,733 | +14% |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: Grant revenue increased 69% YoY to $593K, driven by a $242K increase in grant revenue year-to-date.
- EPS story: The net loss per share widened due to a 14% increase in weighted average shares outstanding, partially offset by a $27.2M gain on the VOWST sale.
- One-off check: Gain on sale of VOWST Business $27.2M (non-recurring)

## The good

- Operating expenses declined 27% YoY to $16.7M
- Cash and cash equivalents increased to $17.5M

## The bad

- Net loss of $16.3 million
- Grant revenue of $593K remains low

## The ugly

- none

## Open questions

- The company expects to fund operations through Q1 2027, excluding potential partnerships or capital sources.
- The release does not disclose the specific amount of the $12.5 million Milestone Termination Payment received from Nestlé in October.

## Full release

### Seres Therapeutics (MCRB) earnings release, November 4, 2026

Seres Therapeutics, Inc. (MCRB) · Form 8-K, Item 2.02 · Filed 2026-11-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526446185/)

SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING

DEVELOPMENT OF

SER-155

TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)

Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for

SER-155

Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027

Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response of diarrhea following treatment with

SER-155

CAMBRIDGE, Mass., November 4, 2026 — Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the

Company), a leading live biotherapeutics company, today reported third quarter 2026 financial results and announced it is progressing plans for a next study evaluating

SER-155 for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC) in patients initiating immune checkpoint inhibitor (ICI) cancer therapy, which is expected to include a dose optimization component. The Company anticipates submitting the study design to the FDA in the first quarter of 2027.

The planned study builds on previously announced positive topline results from an investigator-sponsored trial (IST) conducted at Memorial Sloan Kettering Cancer Center (MSK) in patients with moderate-to-severe irEC, in which 80% of participants achieved an immunosuppressive-free clinical response at Day 15, following treatment with

SER-155.

SER-155 was well tolerated, with no drug-related serious adverse events observed. irEC is a frequent and debilitating adverse reaction associated with widely used ICI cancer therapy that often requires patients to halt life-saving ICI treatment and begin systemic immunosuppressive corticosteroids. irEC is listed as an adverse reaction in the labels of all approved ICIs, including

PD-1 inhibitors (Keytruda®, Opdivo®, Zynyz®),

PD-L1 inhibitors (Imfinzi®, Bavencio®),

CTLA-4 inhibitors (Yervoy®, Imjudo®), and

LAG-3 inhibitor (Opdualag) - all of which were therapies received by patients in the IST.

“The irEC IST provided promising evidence that orally administered

SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with

ICI-induced enterocolitis, “ said Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres. “Based on those results, and in consultation with key opinion leaders in the field, we determined that developing

SER-155 to prevent irEC could address a significant unmet clinical need in patients being treated with ICIs for their cancer. We believe

SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment. We also think this development approach offers a time and capital efficient path to clinical data and positions

SER-155 to potentially address a broad

ICI-treated population and look forward to submitting our planned study design to the FDA in the first quarter of 2027. We are pleased to have two oncology-focused programs for

SER-155, one with the goal of preventing irEC, and the other, in allogeneic hematopoietic stem cell transplant (allo-HCT), aimed at reducing the risk of bloodstream infections, a leading cause of mortality in these patients. We continue to seek capital through partnerships and other sources to advance our programs in irEC and in allo-HCT, which is Phase 2 ready, pending funding.”

Recent Highlights

SER-155 for the prevention of irEC

Broader pipeline and portfolio

Corporate Updates

Third Quarter 2026 Financial Results

Cash and Cash Runway

As of September 30, 2026,

Seres had $17.5 million in cash and cash equivalents. Based on Seres’ currently available cash resources, including the $12.5 million payment received from Nestlé in October, and considering future operating plans, the Company expects to fund operations through the first quarter of 2027. This projection excludes proceeds from any potential future partnerships or other sources of capital.

About Seres Therapeutics

Seres Therapeutics, Inc.

(Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products in oncology that address causes of mortality and discontinuation of life-saving cancer treatment, and in inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science.

SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), and is Phase 2 ready, pending receipt of funding.

SER-155 is also being developed to prevent immune checkpoint inhibitor-related enterocolitis (irEC), with the aim of enabling patients to continue their ICI cancer therapy and avoid the need for immunosuppressive steroid treatment. Following promising results from an investigator-sponsored trial, Seres plans to submit the... (truncated)FDA. The Company is advancing

IND-enabling studies for

SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres’ biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and overgrowth of harmful bacteria in the GI tract. For more information, please visit www.serestherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about:

SER-155 and its intended uses and benefits in irEC; our clinical development plans for

SER-155,

SER-603 and

SER-428, including the design and timing of the next planned study of

SER-155 for the prevention of irEC; potential accessibility for patients; planned submissions to and/or engagement with regulatory authorities, including the anticipated timing of FDA feedback; the timing and results of clinical studies and data readouts; the anticipated content and timing of upcoming presentations and conferences; current or future product candidates and their potential impacts and outcomes; the size of potential patient populations and markets and the potential commercial opportunity for

SER-155; engagement with potential partners and financing sources; our ability to access capital to advance our programs;

IND-enabling activities; our cash runway; the anticipated effects of our lease termination, including expected reductions in facility-related costs; our planned strategic focus; the anticipated timing of any of the foregoing; and other statements that are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (7) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The

Nasdaq Stock Market LLC; (8) our novel approach to therapeutic intervention; (9) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10) our ability to achieve market acceptance necessary for commercial success; (11) the competition we will face; (12) our ability to protect our intellectual property; (13) impact of our recent management transitions and appointments and our ability to retain key personnel; and

(14) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form

10-Q for the quarterly period ended September 30, 2026, to be filed with the Securities and Exchange Commission (SEC), as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

#### Financial statements

##### Income Statement (Three Months Ended September 30, — (unaudited, in thousands, except share and per share data))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Revenue:** | | | | |
| Grant revenue | 593 | 351 | 1,687 | 351 |
| Total revenue | 593 | 351 | 1,687 | 351 |
| **Operating expenses:** | | | | |
| Research and development expenses | 5,592 | 12,616 | 27,928 | 37,376 |
| General and administrative expenses | 5,448 | 9,476 | 20,579 | 31,617 |
| Impairment of long-lived assets | 5,705 |  | 11,512 |  |
| Manufacturing services |  | 736 |  | 5,952 |
| Total operating expenses | 16,745 | 22,828 | 60,019 | 74,945 |
| Loss from operations | -16,152 | -22,477 | -58,332 | -74,594 |
| **Other income (expense):** | | | | |
| Gain on sale of VOWST Business |  | 27,222 | 25,000 | 79,588 |
| Interest income | 146 | 618 | 652 | 1,782 |
| Other income (expense) (1) | -280 | 2,841 | 1,062 | 14,255 |
| Total other income (expense), net | -134 | 30,681 | 26,714 | 95,625 |
| Net (loss) income and comprehensive (loss) income | -16,286 | 8,204 | -31,618 | 21,031 |
| Net (loss) income per share attributable to common stockholders - basic | -1.63 | 0.94 | -3.24 | 2.41 |
| Net (loss) income per share attributable to common stockholders - diluted | -1.63 | 0.94 | -3.24 | 2.4 |
| Weighted average common shares outstanding - basic | 9,982,031 | 8,758,692 | 9,764,763 | 8,735,418 |
| Weighted average common shares outstanding - diluted | 9,982,031 | 8,771,519 | 9,764,763 | 8,744,797 |

##### Balance Sheet (September 30, 2026 — (unaudited, in thousands, except share and per share data))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **Current assets:** | | |
| Cash and cash equivalents | 17,528 | 45,766 |
| Accounts receivable due from SPN - related party | 12,500 | 360 |
| Accounts receivable | 183 | 157 |
| Prepaid expenses and other current assets | 4,212 | 3,093 |
| Total current assets | 34,423 | 49,376 |
| Property and equipment, net | 2,999 | 7,635 |
| Operating lease assets | 27,662 | 72,483 |
| Restricted cash | 773 | 8,668 |
| Other non-current assets | 31 | 31 |
| Total assets | 65,888 | 138,193 |
| **Current liabilities:** | | |
| Accounts payable | 1,461 | 1,682 |
| Accrued expenses and other current liabilities | 3,504 | 3,972 |
| Accrued liabilities due to SPN - related party | 3,278 | 3,278 |
| Operating lease liabilities | 12,650 | 10,390 |
| Total current liabilities | 20,893 | 19,322 |
| Operating lease liabilities, net of current portion | 23,122 | 72,576 |
| Other long-term liabilities | 514 | 2,077 |
| Total liabilities | 44,529 | 93,975 |
| **Stockholders’ equity:** | | |
| Common stock, $0.001 par value; 360,000,000 shares authorized at September 30, 2026 and December 31, 2025; 10,049,501 and 9,556,466 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 10 | 10 |
| Additional paid-in capital | 1,025,370 | 1,016,611 |
| Accumulated deficit | -1,004,021 | -972,403 |
| Total stockholders’ equity | 21,359 | 44,218 |
| Total liabilities and stockholders’ equity | 65,888 | 138,193 |

##### Cash Flow (From the 10-Q · Nine Months Ended September 30, — (unaudited, in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities:** | | |
| Net (loss) income | -31,618 | 21,031 |
| **Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:** | | |
| Stock-based compensation expense | 5,364 | 7,641 |
| Depreciation and amortization expense | 1,932 | 3,179 |
| Impairment of long-lived assets | 11,512 |  |
| Non-cash operating lease cost | 5,171 | 6,234 |
| Gain on sale of VOWST business | -25,000 |  |
| Loss on disposal of fixed assets | 354 |  |
| **Changes in operating assets and liabilities:** | | |
| Accounts receivable due from SPN - related party | 360 | 1,642 |
| Accounts receivable | -26 | -351 |
| Prepaid expenses and other current and other non-current assets | 1,244 | 2,701 |
| Accounts payable | -221 | -2,402 |
| Accrued liabilities due to SPN - related party |  | -13,300 |
| Operating lease liabilities | -16,272 | -6,387 |
| Accrued expenses and other current and long-term liabilities | -2,031 | -4,161 |
| Net cash (used in) provided by operating activities | -49,231 | 15,827 |
| **Cash flows from investing activities:** | | |
| Purchases of property and equipment |  | -223 |
| Sales of property and equipment | 66 |  |
| Proceeds from VOWST milestone termination payment | 12,500 |  |
